MPN

Watch Dr. Nikolai Podoltsev, from Yale School of Medicine, discuss the current management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Watch Dr. Lucia Masarova, Dr. Laura C. Michaelis and Celia Militz answer questions about essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed.

Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Because MPNs can cause chronic disease that spans years or even decades, some patients need their significant other to become their caregiver.

Patients and their caregivers may benefit from community support and education following an MPN diagnosis

Treatments with JAK inhibitors are continuing to make their way into the MPN space, providing symptom relief, but not yet a cure.

Patients with MPNs should consult with their treating physician to individualize a healthy, nutritious diet to help ease symptoms.

Researchers may have uncovered new ways to help patients with accelerated-phase and blast-phase MPNs live longer by borrowing therapies from other blood cancers.

Some symptoms of myeloproliferative neoplasms are “pretty broad,” highlighting the importance of open communication with cancer teams to manage the symptoms and improve quality of life.

Two years after receiving FDA approval, Besremi is a preferred treatment option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

A clinical trial studying an accelerated dose of Besremi recently kicked off.

Earlier treatment with Jakafi showed promise in both improving survival and symptom burden in certain patients with myelofibrosis, though physicians often delay Jakafi treatment.

If approved by the FDA later this year, momelotinib could fulfill an area of unmet need for patients with myelofibrosis, according to an expert.

I was shocked when I was diagnosed with a myeloproliferative neoplasm, and have dedicated myself to learning about the disease since.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Comprehensive insight on the various healthcare team members a hematologist-oncologist may work with to optimize care of myeloproliferative neoplasms.

Switching their focus to myelofibrosis, Rami Komrokji, MD, and Ruben Mesa, MD, consider mainstay treatment options in this setting.

Centering their discussion on cornerstone therapies, expert hematologist-oncologists consider the treatment paradigms of essential thrombocythemia and polycythemia vera.

Watch Dr. Aaron Gerds and Dr. Andrew Kuykendall answer questions about myelofibrosis during the CURE Educated Patient MPN Summit.

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms.

Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).